CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for HK Inno.N Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

HK Inno.N Corp
6-8F
Pine Avenue, 100, Eulji-ro, Jung-gu
Phone: +82 264770000p:+82 264770000 CHUNGJU, 28158  South Korea Ticker: 195940195940

Business Summary
HK Inno.N Corp is a Korea-based company mainly engaged in the manufacture and sale of prescription drugs. The Company operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The Company sells its products within domestic market and to overseas markets.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Vice President, Director Dal WonKwak 62
Vice Chairman Sang HyeonYoon 48
Vice President, Director Mu JeongSeo 53
Managing Director Heon JongChi 60
Managing Director Geun SeokSong 55

General Information
Number of Employees: 1,734 (As of 9/30/2024)
Outstanding Shares: 28,329,891 (As of 9/30/2024)
Shareholders: 128,247
Stock Exchange: KDQ
Fax Number: +82 264770699


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024